Protein clearance mechanisms are essential cellular pathways responsible for removing misfolded, damaged, or aggregated proteins from the cell. These systems maintain proteostasis and their dysfunction is central to neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and frontotemporal dementia (FTD)[1][2]. The accumulation of misfolded protein aggregates is a pathological hallmark of these disorders, reflecting failures in one or more clearance pathways. Understanding the molecular mechanisms of protein clearance has become critical for developing disease-modifying therapeutics that can restore proteostasis and prevent neurodegeneration[3].
Proteostasis, or protein homeostasis, is maintained by a delicate balance between protein synthesis, folding, and clearance. The brain is particularly vulnerable to proteostasis failure due to several factors: neurons are post-mitotic and cannot dilute misfolded proteins through cell division, the brain has high metabolic activity generating protein-damaging reactive oxygen species, and many neurodegenerative disease proteins are inherently aggregation-prone[4]. The failure of protein clearance mechanisms precedes clinical symptoms by years to decades, making these pathways attractive therapeutic targets for early intervention.
The ubiquitin-proteasome system is the primary intracellular degradation pathway for short-lived, misfolded, and regulatory proteins. It accounts for approximately 80-90% of intracellular protein degradation and is essential for cellular function[5].
The UPS involves a cascade of enzymatic reactions:
Ubiquitin activation: The E1 enzyme activates ubiquitin in an ATP-dependent manner, forming a thioester bond between the C-terminal glycine of ubiquitin and the active site cysteine of E1[6].
Ubiquitin conjugation: Activated ubiquitin is transferred to the E2 conjugating enzyme, which then works with E3 ubiquitin ligases to recognize specific substrate proteins and attach ubiquitin to lysine residues on the target protein.
Polyubiquitin chain formation: Additional ubiquitin molecules are added to form a polyubiquitin chain. Chains linked through Lys48 are the canonical signal for proteasomal degradation, while Lys63-linked chains serve non-degradative signaling functions[7].
Proteasomal recognition and degradation: The 26S proteasome (composed of the 20S core particle and 19S regulatory particles) recognizes polyubiquitinated substrates, unfolds them using ATPases, translocates them into the 20S core, and degrades them into peptides of 3-22 amino acids in length.
The 26S proteasome consists of two subcomplexes:
20S Core Particle (CP): A barrel-shaped proteolytic chamber composed of four stacked heptameric rings (α₁₋₇β₁₋₇β₁₋₇α₁₋₇). The outer α-rings control substrate entry, while the inner β-rings (β1, β2, β5) contain the proteolytic activities: caspase-like (β1), trypsin-like (β2), and chymotrypsin-like (β5)[8].
19S Regulatory Particle (RP): A lid-like complex that binds to the α-rings of the 20S CP, recognizes polyubiquitinated substrates, removes the ubiquitin chain, and unfolds the substrate for translocation into the core.
Multiple lines of evidence implicate UPS dysfunction in neurodegenerative diseases:
Alzheimer's disease: Proteasome activity is decreased in AD brains, and accumulation of ubiquitinated proteins is found in amyloid plaques and neurofibrillary tangles. Amyloid-beta and tau directly inhibit proteasome activity[9].
Parkinson's disease: Mutations in parkin (an E3 ubiquitin ligase) cause familial PD. Parkin loss-of-function leads to accumulation of its substrates and mitochondrial dysfunction. Lewy bodies contain ubiquitinated proteins[10].
ALS: Mutations in SOD1, TDP-43, and FUS can impair proteasome function. Sporadic ALS also shows evidence of UPS impairment. Proteasome activity correlates with disease progression[11].
Huntington's disease: Mutant huntingtin protein impairs the UPS at multiple levels, including proteasome binding and activity. Polyglutamine expansions make proteins more resistant to degradation[12].
The autophagy-lysosome pathway is the primary degradation pathway for long-lived proteins, protein aggregates, and organelles. There are three major forms of autophagy: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA)[13].
Macroautophagy involves the formation of double-membraned autophagosomes that engulf cytoplasmic cargo and fuse with lysosomes for degradation.
Key Steps:
Initiation: The ULK1 complex (ULK1, ATG13, FIP200, ATG101) is activated by nutrient sensing (mTOR inhibition) or stress signals[14].
Nucleation: The PI3K-III complex (VPS34, VPS15, Beclin-1, ATG14L) generates PI3P on isolation membranes, recruiting additional autophagy proteins.
Expansion: Two ubiquitin-like systems drive expansion: the ATG12 system (ATG12-ATG5-ATG16L1 conjugate) and the LC3 system (LC3-I to LC3-II conversion). LC3-II is incorporated into the autophagosome membrane and serves as a marker for autophagy[15].
Fusion: The completed autophagosome fuses with a lysosome (forming an autolysosome) via SNARE proteins, VAMP8, and STX17.
Degradation: Lysosomal hydrolases degrade the cargo, and the resulting amino acids and building blocks are recycled to the cytoplasm.
Unlike bulk macroautophagy, selective autophagy specifically targets damaged organelles, protein aggregates, or intracellular pathogens. Key selectivity receptors include:
p62/SQSTM1: Binds polyubiquitinated proteins and aggregates, linking them to autophagy. p62 bodies accumulate in many neurodegenerative diseases[16].
NBR1: Another selective autophagy receptor for ubiquitinated cargo.
Optineurin: Targets damaged mitochondria (mitophagy) and ubiquitinated bacteria.
Tollip: Regulates selective autophagy of protein aggregates.
Mitophagy specifically removes damaged mitochondria and is particularly important in neurons with high mitochondrial turnover requirements. Key mitophagy pathways include:
PINK1-Parkin pathway: Upon mitochondrial damage, PINK1 accumulates on the outer mitochondrial membrane, where it phosphorylates ubiquitin and parkin. Activated parkin ubiquitinates mitochondrial outer membrane proteins, leading to recruitment of autophagy receptors[17].
Receptor-mediated mitophagy: BNIP3, NIX, and FUNDC1 directly bind LC3 on mitochondria, independent of parkin.
Microautophagy involves direct engulfment of cytoplasm by lysosomal invaginations. While less characterized than macroautophagy, it participates in organelle turnover and may be particularly important in neuronal homeostasis[18].
CMA selectively degrades proteins containing a KFERQ motif, which is recognized by HSC70 (heat shock cognate 70 kDa protein). The chaperone-cargo complex binds to LAMP-2A on lysosomes and is translocated into the lysosome lumen for degradation[19].
CMA in Neurodegeneration:
The endosomal-lysosomal system provides another route for extracellular and membrane protein degradation.
Extracellular proteins and membrane components are internalized into early endosomes, which mature into late endosomes and fuse with lysosomes for degradation. This pathway is important for clearing secreted disease proteins that may otherwise propagate between cells[21].
Exosomes (30-150 nm extracellular vesicles) can carry misfolded proteins and aggregates away from cells. This may represent a protective mechanism or, alternatively, a pathway for spreading pathology between cells[22].
Molecular chaperones assist protein folding and prevent aggregation. They are classified by their mechanism and function:
HSP70 family: The major cytoplasmic chaperone system. HSPA1A (HSP70-1) and HSPA8 (HSC70) recognize hydrophobic segments of nascent and misfolded proteins. They work with co-chaperones (HSP40, HSP110) in an ATP-dependent cycle. HSP70 induction is neuroprotective in multiple disease models[23].
HSP90: A abundant chaperone that stabilizes many signaling proteins and mutated kinases. HSP90 inhibitors promote degradation of mutant proteins and are being explored therapeutically. TDP-43 and mutant SOD1 are HSP90 clients[24].
HSP40 (DNAJB proteins): Co-chaperones that target substrates to HSP70 and stimulate ATP hydrolysis.
αB-crystallin (HSPB5): A small HSP that prevents protein aggregation. Mutations in CRYAB (encoding αB-crystallin) cause desmin-related myopathy and have been linked to ALS[25].
Misfolded proteins in the endoplasmic reticulum are retrotranslocated to the cytoplasm for ubiquitination and proteasomal degradation. Key components include:
ERAD is particularly important for proteins with mutations that cause misfolding, including many ALS-causing SOD1 and FUS mutations[26].
Amyloid-beta (Aβ) is produced from amyloid precursor protein (APP) via sequential proteolysis by BACE1 (β-secretase) and γ-secretase. Both intracellular and extracellular Aβ are cleared by:
Hyperphosphorylated tau forms neurofibrillary tangles. Tau is cleared by:
Mutations in tau (MAPT) cause frontotemporal dementia with parkinsonism, demonstrating that tau clearance failure is sufficient for neurodegeneration[28].
α-Synuclein is cleared by multiple pathways:
CMA: The major pathway for physiological α-synuclein turnover. Mutant forms (A30P, A53T) are poorly internalized by LAMP-2A[29].
Proteasome: The 26S proteasome can degrade α-synuclein, but oligomers and fibrils are resistant.
Macroautophagy: Both basal and induced autophagy clear α-synuclein aggregates.
LRRK2 mutations (the most common genetic cause of PD) impair macroautophagy, linking PD genetics directly to protein clearance[30].
Mutant SOD1 accumulates as aggregation-prone oligomers that impair multiple cellular functions. Clearance mechanisms include:
TDP-43 is the major protein in cytoplasmic inclusions in sporadic ALS and most FTD cases. Wild-type TDP-43 is normally nuclear but mislocalizes to the cytoplasm in disease. Clearance mechanisms include:
Mutant huntingtin (mHTT) with expanded polyglutamine repeats is cleared by:
Proteasome: The proteasome can degrade mHTT, but polyglutamine expansions reduce degradation efficiency[33]
Autophagy: Both macroautophagy and CMA contribute to mHTT clearance. Autophagy induction is protective in HD models
Aggregate sequestration: mHTT is sequestered into aggregates, which may be protective by sequestering toxic soluble species but also represents a failure of clearance[34]
Activators:
Inhibitors (for specific applications):
mTOR inhibitors:
mTOR-independent activators:
CMA activators:
Mitophagy enhancers:
Small molecules:
Biologic approaches:
| Biomarker | Target | Disease | Source |
|---|---|---|---|
| p62 | Autophagy receptor | ALS, AD, PD | CSF |
| LC3 | Autophagosome marker | ALS, AD | CSF |
| Ubiquitinated proteins | UPS substrate | ALS, PD | CSF, blood |
| HSP70 | Chaperone response | AD, PD | Blood |
| Cathepsin D | Lysosomal activity | AD | CSF |
The proteostasis network undergoes age-related decline, which explains the late-onset nature of most neurodegenerative diseases[1:1]. Multiple components of the clearance systems show decreased activity with aging:
This age-related decline creates a "window of vulnerability" during which environmental stresses or genetic factors can trigger proteostasis failure and neurodegeneration.
Hardy J, Selkoe DJ. 'The amyloid hypothesis of Alzheimer''s disease: progress and problems on the road to therapeutics'. Science. 2002. ↩︎ ↩︎
Soto C, Estrada LD. 'Protein misfolding and neurodegeneration: lessons from the understanding of Aβ, α-synuclein and polyglutamine aggregation in Alzheimer''s, Parkinson''s and Huntington''s diseases'. Arch Neurol. 2008. ↩︎
Hipp MS, Kasturi P, Hartl FU. The proteostasis network and its decline with ageing. Nat Cell Biol. 2019. ↩︎
Kaganovich D, Kopito R, Frydman J. Misfolded proteins are distinguished by their differential aggregation patterns. Nat Cell Biol. 2008. ↩︎
Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature. 2003. ↩︎
Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998. ↩︎
Komander D, Rape M. The ubiquitin code. Annu Rev Biochem. 2012. ↩︎
Tanaka K. 'The proteasome: overview and functions'. Proc Jpn Acad Ser B Phys Biol Sci. 2023. ↩︎
Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition leads to early learning deficit and neuronal protein modifications. Exp Neurol. 2023. ↩︎
Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998. ↩︎
Cheroni C, De Mario M, Giannini M, et al. Impairment of the ubiquitin-proteasome system in ALS. Brain Res. 2023. ↩︎
Jana NR, Tanaka M, Nukina N. Polyglutamine toxicity is attenuated by the proteasome in a cell model of Huntington's disease. J Neurochem. 2023. ↩︎
Mizushima N, Klionsky DJ. 'Protein turnover via autophagy: implications for metabolism'. Cell. 2007. ↩︎
Ganley IG, Lam DH, Wang J, et al. ULK1 complex. J Biol Chem. 2009. ↩︎
Mizushima N, Yoshimori T, Ohsumi Y. The role of Atg proteins in autophagosome formation. Annu Rev Cell Dev Biol. 2023. ↩︎
Komatsu M, Waguri S, Koike M, et al. Homeostatic and adapter protein p62 in autophagy. Mol Cell Biol. 2023. ↩︎
Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria. J Cell Biol. 2008. ↩︎
Li SC, Han L, Han H. Microautophagy in mammalian cells. Cell Mol Life Sci. 2023. ↩︎
Cuervo AM, Dice JF. A receptor for the selective uptake and degradation of proteins by lysosomes. Science. 1996. ↩︎
Martinez-Vicente M, Talloczy Z, Wong E, et al. Cargo recognition failure underlies defective autophagy. Neuron. 2008. ↩︎
Hu YB, Zou L, Sun Y. Endolysosomal pathway and neurodegenerative diseases. J Neurochem. 2023. ↩︎
Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular functions of exosomes. Traffic. 2024. ↩︎
Morimoto RI. 'The heat shock response: systems biology of proteotoxic stress in aging and disease'. Cold Spring Harb Symp Quant Biol. 2023. ↩︎
Luo W, Sun W, Taldone T, et al. HSP90 in neurodegenerative diseases. Mol Neurodegener. 2024. ↩︎
Vicart P, Caron A, Guicheney P, et al. A missense mutation in the alphaB-crystallin gene causes a myopathy. Nat Genet. 1998. ↩︎
Kimata Y, Hellman U, Yoshida H, et al. ERAD and the biology of protein quality control. Semin Cell Dev Biol. 2023. ↩︎
Saido TC, Leissring MA. Proteolytic degradation of amyloid-β peptide. Cold Spring Harb Perspect Med. 2023. ↩︎
Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration. Nat Rev Neurosci. 2023. ↩︎
Cuervo AM, Stefanis L, Fredenburg R, et al. Impaired degradation of mutant α-synuclein. Science. 2004. ↩︎
gdGD Ramirez P, Liu B, Yang L, et al. LRRK2 and autophagy in Parkinson's disease. Nat Rev Neurol. 2023. ↩︎
Boillee S, Cleveland DW. 'Redirecting SOD1: strategies to prevent neurodegeneration'. Nat Rev Neurosci. 2008. ↩︎
Neumann M, Sampathu DM, Kwong LK, et al. TDP-43 pathology in ALS. Science. 2006. ↩︎
Venkatraman P, Wetzel R, Tanaka A, et al. Cleavage of polyglutamine-expanded huntingtin by the proteasome. J Biol Chem. 2023. ↩︎
Saudou F, Finkbeiner S. 'Huntington''s disease: a journey from understanding to therapy'. Nat Rev Neurosci. 2019. ↩︎
Solimando L, Liu PP, Finley G, et al. Proteasome activators and neurodegenerative diseases. Mol Cell Proteomics. 2023. ↩︎
Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006. ↩︎
Fleming A, Noda T, Yoshimori T, et al. Chemical modulators of autophagy as biological probes and therapeutic agents. Nat Chem Biol. 2023. ↩︎
Kiffin R, Christian C, Knecht E, Cuervo AM. Activation of chaperone-mediated autophagy during oxidative stress. Mol Biol Cell. 2023. ↩︎
Ryu D, Mouchiroud L, Andreux PA, et al. NAD+ repletion improves mitochondrial function in aged mice. Cell Metab. 2023. ↩︎
Soto C, Castillo O, Gutierrez M, et al. Protein aggregation inhibitors as therapeutic agents. Nat Rev Drug Discov. 2023. ↩︎
Eriksson M, Lotfi R, Nagai M, et al. Antibody-based therapy for neurodegenerative diseases. Nat Rev Neurol. 2024. ↩︎
Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2021. ↩︎